title: Radionuclide imaging in urology.
abstract: Radiopharmaceutic tracers are used commonly to diagnose and monitor benign and malignant conditions of the genitourinary system. Most often, these tracers assess renal function and obstruction in "normal" and transplanted renal units. More recently, especially with the advent of positron emission tomography (PET)/CT, the role of nuclear pharmaceutics in the staging and monitoring of malignancies has expanded.
authors.affiliation: Department of Radiology, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA. rgoldfar@chpnet.org
authors.forename: C Richard
authors.initials: CR
authors.lastname: Goldfarb
authors.forename: Neil C
authors.initials: NC
authors.lastname: Srivastava
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Grotas
authors.forename: Fukiat
authors.initials: F
authors.lastname: Ongseng
authors.forename: Harris M
authors.initials: HM
authors.lastname: Nagler
mesh_terms: D006801:Humans; D007674:Kidney Diseases / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D014570:Urologic Diseases / Q000000981:diagnostic imaging*; D014571:Urologic Neoplasms / Q000000981:diagnostic imaging
chemical_list: D019275:Radiopharmaceuticals